Osteopontin role in community-Acquired Pneumonia (CAP).

R. Sharshar (Tanta, Egypt)

Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis  
Session: Discussion of vaccines, biomarkers and risk factors analysis  
Session type: Poster Discussion
Number: 4518
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Sharshar (Tanta, Egypt). Osteopontin role in community-Acquired Pneumonia (CAP).. 4518

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP)
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015


Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014


Matrix metalloproteinases (MMPs) and acute phase proteins (APP) in predicting the efficacy of intensive phase treatment (IPP) in patients with pulmonary tuberculosis (PT)
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Biomarkers and community-adquired pneumonia (CAP) etiology
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012


Beta-catenin and periostin in interstitial pneumonia (IP) of extrinsic (EIP) and unknown (IIP) origin
Source: Virtual Congress 2021 – Chronic airway, interstitial, pleural and neoplastic diseases
Year: 2021


Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015


Role of procalcitonin (PCT) as a marker of severity of community acquired bacterial pneumonia (CABP) compared to PSI, CRB65 abd CURB65
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013


Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013

Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 805s
Year: 2006

Biomarkers in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012

Role of virus in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Fungal, viral and other infections
Year: 2012

C Reactive Protein (CRP), procalcitonin (PCT) and proadrenomedullin (Pro-ADM), as markers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010


System biology (SB) allows the identification of pathogenic micro RNA (miR) in BOS
Source: International Congress 2015 – Pathogenic mechanisms of lung transplant complications: a focus on CLAD
Year: 2015

The pathogen-host interactions in pulmonary tuberculosis (PT)
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014

Induction of neutrophil extracellular traps (NETs) by the pneumococcal toxin, pneumolysin (Ply)
Source: International Congress 2015 – Advances from translational research in respiratory infections
Year: 2015

Impact of neutrophil function on outcomes of community-acquired pneumonia (CAP) in patients with cancer
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007


LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE)
Source: International Congress 2019 – Exacerbations of airway diseases
Year: 2019

Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016


The role of serum inflammatory markers in the detection of ventilation associated pneumonia (VAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009


Soluble form of CD95 (Fas/Apo-1) in patients with community-acquired pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 320s
Year: 2004